{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:21:28Z","timestamp":1767896488879,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T00:00:00Z","timestamp":1517184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG13466"],"award-info":[{"award-number":["IG13466"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG5220"],"award-info":[{"award-number":["IG5220"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","award":["1-12-2008"],"award-info":[{"award-number":["1-12-2008"]}],"id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003980","name":"Istituto Toscano Tumori","doi-asserted-by":"publisher","award":["15-12-2014"],"award-info":[{"award-number":["15-12-2014"]}],"id":[{"id":"10.13039\/501100003980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003981","name":"Agenzia Spaziale Italiana","doi-asserted-by":"publisher","award":["2016-6-U.0"],"award-info":[{"award-number":["2016-6-U.0"]}],"id":[{"id":"10.13039\/501100003981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Stem Cell Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.scr.2018.01.038","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T12:37:11Z","timestamp":1517402231000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose"],"prefix":"10.1016","volume":"28","author":[{"given":"Silvia","family":"Bono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Persio","family":"Dello Sbarba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-4094","authenticated-orcid":false,"given":"Matteo","family":"Lulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.scr.2018.01.038_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052564","article-title":"Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells","volume":"7","author":"Belle","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.scr.2018.01.038_bb0010","doi-asserted-by":"crossref","first-page":"84810","DOI":"10.18632\/oncotarget.13319","article-title":"Different BCR\/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction","volume":"7","author":"Bono","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.scr.2018.01.038_bb0015","unstructured":"Bono, S., Dello Sbarba, P., Lulli, M., 2018. Data on the effect of Imatinib on survival\/growth and stem cell potential of KCL22 cells subjected to glucose shortage. (Data in Brief submitted)."},{"key":"10.1016\/j.scr.2018.01.038_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-1-4939-4011-0_7","article-title":"The Culture Repopulation Ability (CRA) assay and incubation in low oxygen to test antileukemic drugs on imatinib-resistant CML stem-like cells","volume":"1465","author":"Cheloni","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.scr.2018.01.038_bb0025","first-page":"4979474","article-title":"The leukemic stem cell niche: adaptation to \u201chypoxia\u201d versus oncogene addiction","author":"Cheloni","year":"2017","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.scr.2018.01.038_bb0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","article-title":"Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine","volume":"130","author":"Cheloni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.leu.2401744","article-title":"The expansion of murine bone marrow cells preincubated in hypoxia as an in vitro indicator of their marrow-repopulating ability","volume":"14","author":"Cipolleschi","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.scr.2018.01.038_bb0040","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.2174\/1381612811319300006","article-title":"The Culture-Repopulating Ability assays and incubation in low oxygen: a simple way to test drugs on leukaemia stem or progenitor cells","volume":"19","author":"Cipolleschi","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.scr.2018.01.038_bb0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.scr.2018.01.038_bb0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1432-0436.1984.tb01423.x","article-title":"Haemopoietic cell growth factor and glucose transport. Its role in cell survival and the relevance of this in normal haemopoiesis and leukaemia","volume":"27","author":"Dexter","year":"1984","journal-title":"Differentiation"},{"key":"10.1016\/j.scr.2018.01.038_bb0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.scr.2018.01.038_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.24247","article-title":"Chronic myeloid leukemia: second-line drugs of choice","volume":"91","author":"Gambacorti-Passerini","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.scr.2018.01.038_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2012.27","article-title":"Aberrant expression and biological significance of Sox2, an embryonic stem cell transcriptional factor, in ALK-positive anaplastic large cell lymphoma","volume":"2","author":"Gelebart","year":"2012","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.scr.2018.01.038_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/stem.769","article-title":"Concise review: cancer stem cells and minimal residual disease","volume":"30","author":"Ghiaur","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.scr.2018.01.038_bb0075","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.leu.2404224","article-title":"Hypoxia suppresses BCR\/Abl and selects imatinib-insensitive progenitors within clonal CML populations","volume":"20","author":"Giuntoli","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.scr.2018.01.038_bb0080","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3324\/haematol.2010.029082","article-title":"Lucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate","volume":"96","author":"Giuntoli","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.scr.2018.01.038_bb0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0095","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2141.2000.01842.x","article-title":"Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors","volume":"108","author":"Ivanovic","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.scr.2018.01.038_bb0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0301-472X(01)00765-2","article-title":"Hypoxia maintains and interleukin-3 reduces the pre-colony-forming cell potential of dividing CD34(+) murine bone marrow cells","volume":"30","author":"Ivanovic","year":"2002","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.scr.2018.01.038_bb0105","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1182\/blood-2002-05-1324","article-title":"Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo","volume":"100","author":"Jiang","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0110","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/ijms18030486","article-title":"NANOG expression as a responsive biomarker during treatment with hedgehog signal inhibitor in acute myeloid leukemia","volume":"18","author":"Kakiuchi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.scr.2018.01.038_bb0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0120","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/jrr\/rrs025","article-title":"Coenzyme Q10 protects retinal cells from apoptosis induced by radiation in vitro and in vivo","volume":"53","author":"Lulli","year":"2012","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.scr.2018.01.038_bb0125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.scr.2018.01.038_bb0130","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1073\/pnas.0701152104","article-title":"Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia","volume":"104","author":"Parmar","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.scr.2018.01.038_bb0135","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4161\/15384101.2014.964107","article-title":"The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy","volume":"13","author":"Rovida","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.scr.2018.01.038_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/bjc.1968.34","article-title":"The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour","volume":"22","author":"Tannock","year":"1968","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.scr.2018.01.038_bb0145","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0150","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/j.1460-2075.1984.tb01821.x","article-title":"Haemopoietic cell growth factor mediates cell survival via its action on glucose transport","volume":"3","author":"Whetton","year":"1984","journal-title":"EMBO J."},{"key":"10.1016\/j.scr.2018.01.038_bb0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2009-07-233437","article-title":"Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches","volume":"116","author":"Winkler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.scr.2018.01.038_bb0160","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1179\/1973947813Y.0000000087","article-title":"Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells","volume":"25","author":"Witort","year":"2013","journal-title":"J. Chemother."},{"key":"10.1016\/j.scr.2018.01.038_bb0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1254\/jphs.13025FP","article-title":"Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties","volume":"122","author":"Xin","year":"2013","journal-title":"J. Pharmacol. Sci."}],"container-title":["Stem Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1873506118300448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1873506118300448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:31:00Z","timestamp":1761737460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1873506118300448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":33,"alternative-id":["S1873506118300448"],"URL":"https:\/\/doi.org\/10.1016\/j.scr.2018.01.038","relation":{},"ISSN":["1873-5061"],"issn-type":[{"value":"1873-5061","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose","name":"articletitle","label":"Article Title"},{"value":"Stem Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scr.2018.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}